stoxline Quote Chart Rank Option Currency Glossary
Clearside Biomedical, Inc. (CLSD)
1.03  0.02 (1.98%)    11-28 14:41
Open: 1
High: 1.03
Volume: 41,666
Pre. Close: 1.01
Low: 1
Market Cap: 64(M)
Technical analysis
2023-11-28 2:17:09 PM
Short term     
Mid term     
Targets 6-month :  1.38 1-year :  1.62
Resists First :  1.19 Second :  1.38
Pivot price 0.97
Supports First :  0.85 Second :  0.64
MAs MA(5) :  0.99 MA(20) :  0.95
MA(100) :  0.95 MA(250) :  1.1
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  58.9 D(3) :  57.4
RSI RSI(14): 57.7
52-week High :  1.85 Low :  0.64
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CLSD ] has closed below upper band by 37.5%. Bollinger Bands are 3.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.06 - 1.07 1.07 - 1.07
Low: 0.99 - 0.99 0.99 - 1
Close: 1 - 1.01 1.01 - 1.02
Company Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Headline News

Thu, 16 Nov 2023
Clearside Biomedical Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Tue, 07 Nov 2023
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting - Yahoo Finance

Mon, 06 Nov 2023
BioCryst pays $5M upfront in licensing deal for vision-loss treatment - The Business Journals

Mon, 06 Nov 2023
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation - Simply Wall St

Tue, 31 Oct 2023
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023 - Yahoo Finance

Thu, 26 Oct 2023
3 Cheap Stocks to Buy Under $1 in October 2023 - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 62 (M)
Held by Insiders 5.395e+007 (%)
Held by Institutions 7.1 (%)
Shares Short 351 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.993e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -821.2 %
Return on Assets (ttm) -41.7 %
Return on Equity (ttm) -1 %
Qtrly Rev. Growth 2.21e+006 %
Gross Profit (p.s.) 102.24
Sales Per Share 142.21
EBITDA (p.s.) 513761
Qtrly Earnings Growth -0.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -10.49
Stock Dividends
Dividend 0
Forward Dividend 290630
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android